ChromaDex extends partnership with Matakana Health until 2023 with distribution in Australia

December 5, 2019

This continued partnership will now expand distribution into Australia, where ChromaDex recently received approval for its nicotinamide riboside chloride as an ingredient in listed Complementary Medicines from the Australian Therapeutic Goods Administration.

ChromaDex (Los Angeles, CA) has extended its partnership with Matakana Health (MHL; Auckland, New Zealand), a dietary supplement manufacturer and distributor, until 2023. This continued partnership will now expand distribution into Australia, where ChromaDex recently received approval for its nicotinamide riboside chloride (NR, or Niagen) as an ingredient in listed Complementary Medicines from the Australian Therapeutic Goods Administration. MHL has distribution in New Zealand and Australia in both online and offline channels.

“Matakana successfully launched Tru Niagen in New Zealand in 2018,” said ChromaDex CEO Rob Fried, in a press release. “We look forward to building on that momentum together as we expand into Australia.”

“We are excited to be expanding our relationship with ChromaDex in Oceania. Tru Niagen has been taken up by New Zealanders with great enthusiasm, and we expect to see the same level of excitement and adoption of this groundbreaking product from Australians in 2020,” added Matakana Health CEO Kevin Glucina, in a press release.